Teva in-licensed the exclusive rights for Circadin® for the treatment of primary insomnia in Israel and became a strategic partner. Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development, production and marketing of ethical, generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.With more than a century of experience in the healthcare industry, the Company enjoys a firmly established international presence, operating through a carefully tailored network of worldwide subsidiaries. Headquartered in Israel, above 80% of Teva’s sales, which totaled US$11.1 billion in 2008, are in North America and Europe. Teva has over 38,000 employees worldwide and production facilities in Israel, North America, Europe and Latin America.
For further information, please visit www.tevapharm.com
Takeda Pharmaceuticals International GmbH
Takeda is marketing Circadin® in Belgium, Netherlands, Greece, the Baltic States, Norway, Sweden, Finland, Denmark, Iceland, Luxembourg and South Africa.
Takeda Pharmaceuticals International GmbH, headquartered in Zurich, is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As the largest pharmaceutical company in Japan and a leader in the global industry, Takeda’s mission is to strive toward better health for patients worldwide through leading innovation in medicine. It has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. Takeda’s commercial presence mainly covers the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.
For further information, please visit www.takeda.com
Aspen Pharmacare is marketing Circadin® in Australia and New Zealand. Aspen Pharmacare Australia is a subsidiary of Aspen Pharmacare Holdings Limited, the largest listed pharmaceutical company in South Africa.
Aspen Pharmacare Australia commenced operations in May 2001 with a portfolio of products generating sales of $10.5 million. Its current annualized sales are over AU$ 230 million and growing.
For further information, please visit www.aspenpharma.com.au
DKSH is marketing Circadin® in Thailand.
Diethelm Limited is a member of the DKSH Group, which formed following the mergers of three Swiss companies: Diethelm, Keller, and SiberHegner in 2000 and 2002.
Established in 1906 on the banks of Chao Phraya River, today the company is one of Thailand’s leading business organizations, with annual sales of THB 98 billion in 2008. It has over 10,000 employees and a comprehensive network of 203 branches all across the country. It is the largest marketing, distribution, and logistics service provider in Thailand.
For further information, please visit www.dksh.co.th
Kuhnil Pharm is a pharmaceutical company established in Korea. The company speciliazes in manufacturing, distributing, importing, and exporting pharmaceutical products in the musculoskeletal, infection, cardiovascular, respiratory, CNS, endocrinological and allergy therapeutic areas.
For further information, please visit www.kuhnil.com
MEDICE is marketing Circadin® in Germany.
MEDICE is a fully-integrated, mid-sized and family-owned German pharmaceutical enterprise based in Iserlohn with capabilities in research & development, manufacturing, quality control & assurance, regulatory & medical affairs as well as marketing & sales of high-quality drugs, pharmaceutical products and medical devices.
For further information, please visit www.medice.de
Flynn Pharma is marketing Circadin® in UK & Ireland.
Flynn Pharma is a UK-based pharmaceutical company, incorporated in 2006, with significant presence in the UK and Ireland. It is focused on hospital and specialty sectors and has a robust portfolio of over 60 marketed product lines in the UK & Ireland.
For further information, please visit www.flynnpharma.com
Italfarmaco is marketing Circadin® in Portugal.
Founded in June, 1999, Italfarmaco Portugal belongs to the Italfarmaco Group founded in 1938 in Milan, Italy. Today, the Italfarmaco group is present in several European countries and in the main markets in South America. Since its foundation in 1999, Italfarmaco has been committed with its values: being ethic, offering health solutions, developing and providing high quality pharmaceutical products with scientific and technologic innovations.
For further information, please visit www.italfarmaco.it
Ipsen is marketing Circadin® in Russia.
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Its development strategy is supported by four franchises: neurology, endocrinology, uro-oncology and hemophilia. The company’s R&D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins.
For further information, please visit www.ipsen.com
BIOCODEX is marketing Circadin® in France.
BIOCODEX is a French independent pharmaceutical company founded in the 1950’s to develop and distribute a promising probiotic medication. Since then, BIOCODEX has expanded its range by developing products of its own research , as well as redeveloping products acquired from other companies. BIOCODEX now specializes in several therapeutic areas: Gastroenterology, Neurology, Psychiatry, Pediatrics and Pain relief Treatment. BIOCODEX exports its products to more than 100 countries with 170 million euros in consolidated revenue in 2011.
For further information, please visit www.biocodex.com
Sanova is marketing Circadin® in Austria.
Sanova Pharma GesmbH, as part of the Celesio Healthcare group, is a leading pharmaceutical and med-tech company in Austria. The company offers RX-pharmaceuticals, OTC-products and medical systems, and serves hospitals, laboratories, universities, physicians, biotech clients and patients. Sanova was founded in 1946 and has extensive experience in marketing, distribution, and logistics services to pharmaceutical industries in Austria.
For further information, please visit www.sanova.at
Exeltis is marketing Circadin® in Spain.
Exeltis is the result of the natural evolution and sustained growth of the pharmaceutical business of CHEMO, an integrated group engaged in life sciences. Exeltis combines the knowledge and experience gained by the Group in almost forty years with the values of entrepreneurial spirit, diversity and excellence. With a sound positioning in the Women’s Health, Central Nervous System, Respiratory, Dermatology and Ophthalmology, it has a portfolio of almost 300 medicines.
With a presence in more than 40 countries, 4,000 professionals, 33 worldwide affiliates and a global manufacturing network with facilities in Europe, America and Asia, it is an organization with ample capacity to develop, produce and facilitate treatment for millions of people around the world.
For further information, please visit www.exeltis.com
Fidia is marketing Circadin® in Italy.
Founded in 1946, Fidia farmaceutici spa is headquartered in Abano Terme, Italy, and is a fully integrated healthcare Company, with R&D, manufacturing, marketing and sales capabilities. Fidia operates worldwide to develop and market patented, innovative products of its own research, mainly based on hyaluronan and its derivatives, as well as selected products in specific therapeutic areas licensed from other companies. The company is focused on specialty and hospital sectors and consumers, and has a robust portfolio of marketed product lines (RX-pharmaceuticals, OTC-products, medical devices and nutraceuticals) in major therapeutic areas, such as musculoskeletal disorders, Advanced Wound Care, and CNS. The company is continually expanding its position in major pharmaceutical markets, such as the U.S. and Central Asia, where it has established a sound presence through its wholly-owned subsidiaries.
For further information, please visit www.fidiapharma.com
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 8 600 people in approximately 40 countries, the company generated revenue of € 3.3 billion in 2014. UCB is listed on Euronext Brussels (ticker: UCB).
UCB partners with the leaders in the pharmaceutical industry to resolve the complexities related to severe disease treatment, which are beyond the expertise and resources of a single organization.
For further information, please visit www.ucb.com
Biopas Laboratories is a company that offers solutions to unmet clinical needs for the medical community and patients in Latin America. Biopas has presence in over 15 countries in the region. Its portfolio of products resulting from business relationships with more than 30 R & D laboratories.
Presently close to have 500 employees, its sales goal for 2015 is 135 million dollars and plans to reach over 250 Million Dollars in 2019. The focus of Biopas is in critical illness and special care to patients.
For further information, please visit www.biopasgroup.com